Studies from School of Medicine Have Provided New Information about Pulmonary Fibrosis (Idiopathic Pulmonary Fibrosis: The Role of Pathobiology in…

Studies from School of Medicine Have Provided New Information about Pulmonary Fibrosis (Idiopathic Pulmonary Fibrosis: The Role of Pathobiology in Making a Definitive Diagnosis)

By a News Reporter-Staff News Editor at Insurance Weekly News -- Research findings on Lung Diseases and Conditions are discussed in a new report. According to news reporting out of New York City, New York, by VerticalNews editors, the research stated, "Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology characterized by fibrosis of the interstitium, resulting in progressive respiratory insufficiency and shortened lifespan. Treatment focus tends to shift from disease-centered to symptom-centered as the disease progresses."

Our news journalists obtained a quote from the research from the School of Medicine, "Over the years, a number of pharmacologic strategies have been used to treat IPF, albeit without solid evidence demonstrating a beneficial impact on the disease course. The previously held theory that inflammation was the predominant underlying feature of IPF led to the use of corticosteroids and immunosuppressive therapy as the standard of care. However, a greater understanding of the pathogenesis of IPF has evolved and guidelines were developed using evidence-based criteria. Guided by the data, treatment guidelines developed in 2011 stated that no pharmacologic therapy showed a proven benefit for patients with IPF and issued recommendations against the use of most treatments. The treatment landscape changed in October 2014, when the FDA approved pirfenidone and nintedanib for the treatment of IPF. For the first time, clinicians have therapeutic options with demonstrated clinical efficacy to treat patients with IPF."

According to the news editors, the research concluded: "To provide effective high-value care for patients with IPF, healthcare professionals require thorough knowledge and awareness about these medications, including their safety concerns."

For more information on this research see: Idiopathic Pulmonary Fibrosis: The Role of Pathobiology in Making a Definitive Diagnosis. American Journal of Managed Care, 2015;21(14):S276-S283. American Journal of Managed Care can be contacted at: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

Our news journalists report that additional information may be obtained by contacting M. Padilla, Icahn Sch Med Mt Sinai, New York, NY 10029, United States.

Keywords for this news article include: Respirology, Pathobiology, New York City, United States, North and Central America, Respiratory Tract Diseases, Lung Diseases and Conditions, Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC